SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01700582

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) Benefiting From a Molecular Test on the Hospital Platforms of Molecular Genetics.

The French National Cancer Institute (INCa) support a 28 hospital platforms network for molecular testing of cancer patients. These platforms routinely assess a panel of biomarkers in order to speed up access of French cancer patients to targeted therapies (commercially available or through clinical trials). The objective of the BIOMARKERS-France study is to describe the epidemiological, clinical and molecular characteristics of these patients and their tumors and to assess the impact of these analyzes on their treatment (ie bio-guided therapy) as well as outcomes (response rate, progression free and overall survival).

NCT01700582 Carcinoma, Non-Small-Cell Lung ALK Gene Mutation KRAS Gene Mutation BRAF Gene Mutation
MeSH:Carcinoma, Non-Small-Cell Lung
HPO:Non-small cell lung carcinoma


Primary Outcomes

Description: Number of patients with EGF-R gene mutation

Measure: EGF-R gene mutation in nationwide cohort

Time: 1 Year

Secondary Outcomes

Description: Number of patients with K-RAS gene mutation

Measure: K-RAS gene mutation in nationwide cohort

Time: 1 year

Description: Number of patients with EML4-ALK translocation

Measure: EML4-ALK translocation in nationwide cohort

Time: 1 year

Description: Number of patients with BRAF gene mutation

Measure: BRAF gene mutation in nationwide cohort

Time: 1 year

Description: Number of patients with HER2 gene mutation

Measure: HER2 gene mutation in nationwide cohort

Time: 1 year

Description: Number of patients with PI3K gene mutation

Measure: PI3K gene mutation in nationwide cohort

Time: 1 year

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 T790M

Regarding stage IV non-squamous NSCLC patients, 7 biomarkers are assessed including activating EGFR mutations, EML4-ALK translocation and EGFR T790M, KRAS, BRAF, HER2 and PI3KCA mutations. --- T790M ---



HPO Nodes


HPO: